Pharmaceutical giant GlaxoSmithKline is poised to begin developing products based on traditional Chinese medicines as part of its revamped research and development strategy.

    • Please note: The rest of this article is only available to subscribers of the Journal of Chinese medicine. Please subscribe now.

Categories: Herb research

Not yet subscribed?

Subscribe to the Journal of Chinese Medicine now from only £30.00 per year. Your subscription will include:

Subscribe now